Glaser Weil Advises INVO Bioscience in Reverse Merger with NAYA Biosciences

Glaser Weil represented INVO Bioscience, Inc. (Nasdaq: INVO), a global leader in expanding access to advanced fertility treatment, in its definitive merger agreement with NAYA Biosciences Inc., a privately-held company dedicated to increasing patient access to breakthrough treatments in oncology and regenerative medicine.

The transaction—an all-stock reverse merger—is subject to shareholder approval. The combined NASDAQ-listed "NAYA Biosciences" will allow NAYA to expand INVO's footprint of fertility clinic operations across the United States as well as advance the development of NAYA's unique clinical stage portfolio of oncology therapeutics.

The deal was jointly announced on October 23, 2023, and is expected to close in Q4 of 2023.

The Glaser Weil deal team was led by Corporate Partner Marc Indeglia and Associate Gabriel Kiss.

For more information, read the press release.